ALX positive interim phase 2 results in Gastric Cancer trial

 Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors

-- Interim efficacy results showed the confirmed overall response rate for evorpacept combination treatment was 52% compared to 22% for control treatment

https://www.globenewswire.com/news-release/2023/10/03/2753394/0/en/ALX-Oncology-Reports-Positive-Interim-Phase-2-ASPEN-06-Clinical-Trial-Results-of-Evorpacept-for-the-Treatment-of-Advanced-HER2-Positive-Gastric-Cancer.html